Stockreport

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD

Cingulate Inc.  (CING) 
PDF Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application        CTx-1301 Could Benefit 60% of ADHD Patients Currently Using Immediate-Relea [Read more]